Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
December 19, 2020
Lead Product(s) : 188-Re
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : OncoBeta
Deal Size : Undisclosed
Deal Type : Agreement
Details : The Heads of Terms will initiate a Strategic Partnership and Supply Agreement for the development of Rhenium-188 API solutions that are appropriate for labelling the NanoMab range of nanobodies for the production of therapeutic radiopharmaceuticals.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
October 27, 2020
Lead Product(s) : 188-Re
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : OncoBeta
Deal Size : Undisclosed
Deal Type : Agreement
Details : The programme will utilise Nanomab’s next generation NM-02 radiopharmaceutical product targeting a First in Human (FIH) administration to develop novel radiopharmaceutical product for patients with HER2 positive breast cancer.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
May 21, 2020
68Ga-THP-PSMA PET/CT in Prostate Cancer: Clinical Stage and Restage
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
November 12, 2019
HER2 Expression Detection in Breast Cancer Using 99mTc-NM-02
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 01, 2019
Reset All
